Metropolis Healthcare Share Price

    NSE
    1734
    +8.40 (0.52%)
    METROPOLIS • 03 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    -16.71%

    3Y Annualised Return

    6.30%

    5Y Annualised Return

    4.76%

    The current prices are delayed, login or Open Demat Account for live prices.

    Metropolis Healthcare Stock Performance

    1W Return2.69
    1Y Return-14.14
    Today's Low1720.1
    Prev. Close1,725.60
    Mkt Cap (Cr.)9,002.65
    1M Return1.48
    3Y Return20.99
    52-Week High2318.3
    Open1,727.90
    PE Ratio72.03
    6M Return-13.01
    Today's High1749
    52-Week Low1315
    Face Value2

    Metropolis Healthcare Company background

    Founded in: 2000
    Dr. Sushil Kanubhai Shah, one of the Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desais Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards. In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners, in the name and style of Metropolis Lab. In January 1998, Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1, 2002, the business of Metropolis Lab was transferred to Dr. V. K. Desais Hospital as a going concern. In May 2002, Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desais Hospital was changed to Metropolis Health Services in November 2002. Further, in April 2003, Ameera Sushil Shah, Jaswanti Kanubhai Shah, Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services. In July 2003, Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited (MHSIPL). The name of MHSIPL was changed to Metropolis Health Services (India) Limited, pursuant to a Fresh Certificate of Incorporation upon Change of Name to Public Limited Company on March 1, 2006. In January 2009, MHSIL amalgamated with Pathnet India Private Limited, which was a wholly owned subsidiary of MHSIL. Metropolis Healthcare Limited (Formerly known as Pathnet India Private Limited) was incorporated in New Delhi on November 10, 2000. The Company is one of the leading diagnostics companies in India. It has widespread presence across 220 cities in India with leadership position in West and South India. Through its widespread operational network, it offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. It also offers analytical and support services to clinical research organizations for their clinical research projects. Presently, it is engaged in the business of providing pathology and related healthcare services.The Company conducts its operations through their laboratory and service network. It has implemented a hub and spoke model for quick and efficient delivery of services through their widespread laboratory and service network, which covers 197 cities in India. As of December 31, 2018, its laboratory network consists of 115 clinical laboratories, comprising (i) a global reference laboratory (GRL) located in Mumbai, which is the main hub and equipped to conduct majority of the tests offered by them (ii) 14 regional reference laboratories (RRLs) (out of which four are located outside India), which are equipped to conduct routine, semispecialized and few specialized tests (iii) 56 satellite laboratories (out of which one is located outside India), which are equipped to conduct routine and semispecialized tests and (iv) 44 express laboratories (out of which five are located outside India), which are equipped to conduct routine tests. Metropolis Healthcare has been awarded the tender by the National Aids Control Organization (NACO) to collect specimens from 525 governmentowned antiretroviral therapy (ART) centers and conduct HIV1Viral load tests. It also offers analytical services and support services such as logistics and electronic data interchange (EDI) to contract research organizations for their clinical research projects. Outside India, it has laboratory operations in Ghana, Kenya, Zambia, Mauritius and Sri Lanka. In addition, it has also entered into agreements with third parties for collection and processing of specimens in Nepal, Nigeria, UAE and Oman. Metropolis brand is recognized for delivering quality diagnostic and related healthcare tests and services. For instance, it received excellence in customer service and delivery award from Biotrains in 2018, and also received special jury mention for service excellence (diagnostic center) by FICCI at the Healthcare Excellence Awards 2018. In addition, its health campaign was recognized as best in health and fitness in the Digital Campaign Awards 2018 by LH Insights.Metropolis Healthcare Ltd. came out with an Initial Public Offering (IPO) of 13,685,095 equity shares of Face Value of Rs 2/ each of the company for cash at a price of Rs 880 per equity share aggregating Rs 1204.29 Crores, consisting of an offer for sale of 6,272,335 equity shares by Dr. Sushil Kanubhai Shah (the promoter selling shareholder) aggregating to 551.97 Crores and 7,412,760 equity shares by Ca Lotus Investments (the investor selling shareholder) aggregating 652.32 Crores. The face value of equity shares is Rs 2/each. The IPO was priced at Rs 880 per equity share.During the year 201819, the Wholly Owned Subsidiaries viz., Bacchus Hospitality Services and Real Estate Private Limited Metropolis Healthcare (Chandigarh) Private Limited, Metropolis Healthcare (Jodhpur) Private Limited, Sanket Metropolis Health Services (India) Private Limited, Final Diagnosis Private Limited and Golwilkar Metropolis Health Services (India) Private Limited amalgamated with the Company (Transferee Company) effective from 08 September 2018. Further, the Transferee Company on 08 September 2018 allotted 26,57,731 fully paid up Equity Shares of Rs 10/ each in the ratio of 957,713 Equity Shares of Rs 10/ each to the shareholders of Bacchus for every 10,00,000 Equity Shares of Rs 10/ each held in Bacchus (Prebonus and Subdivision). The wellness initiative TruHealth was launched across 36cities in FY19 launched Medengage, to nurture upcoming medical talent. A wide range of 3,487 clinical laboratory tests and 530 profiles were offered by Metropolis as of March 2019. The equity shares of Company were listed on BSE Ltd and the National Stock Exchange of India Limited with effect from April 15, 2019.The Company acquired four frontend labs in Surat in FY 2020. It acquired 51% of stake i.e. 5,100 Equity Shares of Shraddha Diagnostic Centre (I) Private Limited (SDCIPL) from the existing shareholders at a consideration of Rs 9,36,30,000/. It further acquired a total of 550 equity shares of the Target Company (constituting 5.5 % of its Share Capital) on April 7, 2020 for a consideration of Rs 1 Crores.During the year 202021, the Company acquired the balance stake of 49% in Raj Metropolis and with effect from November 5, 2020 and as a result, Raj Metropolis became a whollyowned subsidiary of the Company. In the financial year 202122, Metropolis strengthened its operations by adding 16 labs and 506 network centres, as a part of expansion plan of adding 90 labs and 1,800 network centres by FY 24. It acquired the 100% stake in Dr. Ganesans Hitech Diagnostics Centre Private Limited along with its subsidiary Centralab Healthcare Services Private Limited and post completion of acquisition, Hitech and Centralab became whollyowned subsidiary and step down wholly owned subsidiary respectively of Company effective 22 Oct 2021. Similarly, during the year 202122, Company had acquired balance stake of 35% of Metropolis Histoexpert Digital Services Private Limited, Subsidiary of the Company from Koninklijke Philips N.V. Post the acquisition, Metropolis Histoxpert became the whollyownedSubsidiary of the Company with effect from 26 November 2021.During the year 202223, the Company launched some complex tests using Next Generation Sequencing (NGS) Technology for Prenatal screening, Breast Cancer, Bone Marrow Transplant and Allergy Component Testing powered by Artificial Intelligence. In FY 23, it added 14 labs and approximately 548 centers during the year, built a new management team to run the business, integrated the technology offering with Metropolis and executed some cost synergies further added 83 new tests. During year 202223, the subsidiary companies, M/s. Bokil Golwilkar Metropolis Healthcare Private Limited, M/s. Desai Metropolis Health Services Private Limited, M/s. Dr. Patel Metropolis Healthcare Private Limited, M/s. Lab One Metropolis Healthcare Services Private Limited, M/s. Micron Metropolis Healthcare Private Limited, M/s. R. V. Metropolis Diagnostic Health Care Center Private Limited, M/s. Raj Metropolis Healthcare Private Limited and M/s. Sudharma Metropolis Health Services Private got merged with the Company through the Scheme of Amalgamation, which was made effective from July 11, 2022.The Company expanded its network, marking the presence to 600 towns across India. In 202324, it launched over 100 advanced tests, including Comprehensive testing for food and drug allergies using AI, Syndromic Multiplex PCR Testing for infectious diseases, and Next Generation Sequencingbased tests for various conditions, including predictive biomarkers for cancer immunotherapy. Further, the Next Best Action (NBA) initiativea comprehensive program designed to empower patients and prevent severe complications from chronic diseases launched in FY24.

    As of 03 Jul, 2025, Metropolis Healthcare share price is ₹1737.9. The stock opened at ₹1727.9 and had closed at ₹1725.6 the previous day. During today’s trading session, Metropolis Healthcare share price moved between ₹1,720.10 and ₹1,749.00, with an average price for the day of ₹1734.55. Over the last 52 weeks, the stock has recorded a low of ₹1,315.00 and a high of ₹2,318.30. In terms of performance, Metropolis Healthcare share price has declined by 15.2% over the past six months and has declined by 16.71% over the last year.

    Read More
    Metropolis Healthcare SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹59,83,871 (-7.94%)

    Daily SIP of 25,000 would have become 59,83,871 in 1 year with a gain of -5,16,128 (-7.94%)

    View details of Market Depth

    Metropolis Healthcare Fundamental

    Market Cap (in crs)

    9,002.65

    Face Value

    2

    Turnover (in lacs)

    543.13

    Key Metrics

    Qtr Change %
    25.04% Fall from 52W High
    11.8
    Dividend yield 1yr %
    0

    Metropolis Healthcare Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Metropolis Healthcare Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    345.29 Cr
    322.77 Cr
    349.79 Cr
    313.36 Cr
    331 Cr
    Metropolis Healthcare Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    1346.32 Cr
    1216.83 Cr
    1163.43 Cr
    1245.96 Cr
    1010.03 Cr
    864.97 Cr
    Metropolis Healthcare Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    29.23 Cr
    31.47 Cr
    46.7 Cr
    38.11 Cr
    36.53 Cr
    Metropolis Healthcare Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    145.51 Cr
    128.46 Cr
    143.39 Cr
    214.69 Cr
    183.35 Cr
    128.07 Cr

    Metropolis Healthcare Result Highlights

    • Metropolis Healthcare Ltd reported a 2.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 17.5%.

    • Its expenses for the quarter were up by 0.0% QoQ and 17.0% YoY.

    • The net profit increased 16.1% QoQ and increased 9.1% YoY.

    • The earnings per share (EPS) of Metropolis Healthcare Ltd stood at 7.1 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Metropolis Healthcare

    Promoter
    48.9%
    Foreign Institutions
    15.3%
    Mutual Funds
    26.4%
    Domestic Institutions
    30.3%
    Public
    5.5%
    Promoter
    49.4%
    Foreign Institutions
    16.7%
    Mutual Funds
    26.4%
    Domestic Institutions
    30%
    Public
    3.9%
    Promoter
    49.4%
    Foreign Institutions
    18.6%
    Mutual Funds
    24.3%
    Domestic Institutions
    28%
    Public
    4%
    Promoter
    49.6%
    Foreign Institutions
    18.2%
    Mutual Funds
    23.7%
    Domestic Institutions
    27.5%
    Public
    4.7%
    Promoter
    49.7%
    Foreign Institutions
    18.9%
    Mutual Funds
    21.3%
    Domestic Institutions
    24.9%
    Public
    6.6%
    Promoter
    49.7%
    Foreign Institutions
    21.7%
    Mutual Funds
    16%
    Domestic Institutions
    20.7%
    Public
    7.9%

    Metropolis Healthcare Technical Analysis

    Moving Averages Analysis
    1734
    Current Price
    Bullish Moving Averages
    13
    Bearish Moving Averages
    3
    5Day EMA
    1,719.80
    10Day EMA
    1,711.80
    12Day EMA
    1,709.80
    20Day EMA
    1,703.40
    26Day EMA
    1,699.40
    50Day EMA
    1,692.10
    100Day EMA
    1,721.70
    200Day EMA
    1,784.40
    5Day SMA
    1,714.00
    10Day SMA
    1,709.20
    20Day SMA
    1,704.50
    30Day SMA
    1,694.10
    50Day SMA
    1,689.90
    100Day SMA
    1,668.10
    150Day SMA
    1,778.70
    200Day SMA
    1,874.20
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    15441 Rs
    32538 Rs
    Week Rs
    104411 Rs
    121877 Rs
    Month Rs
    74816 Rs
    104178 Rs
    1,735.67
    Pivot
    Resistance
    First Resistance
    1,751.23
    Second Resistance
    1,764.57
    Third Resistance
    1,780.13
    Support
    First Support
    1,722.33
    Second support
    1,706.77
    Third Support
    1,693.43
    Relative Strength Index
    58.43
    Money Flow Index
    26.27
    MACD
    10.41
    MACD Signal
    8.49
    Average True Range
    40.16
    Average Directional Index
    21.53
    Rate of Change (21)
    2.57
    Rate of Change (125)
    -15.49
    Name
    Holding Percent
    Hdfc Mutual Fund - Hdfc Focused 30 Fund
    9.64
    Uti Value Fund
    3.57
    Kotak Small Cap Fund
    2.92
    Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund
    2.28
    Franklin India Smaller Companies Fund
    2.09
    Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Flexi Cap Fund
    1.54
    Sundaram Mutual Fund A/C Sundaram Services Fund
    1.5
    Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund
    1.13
    J P Morgan Funds
    1.59
    Jpmorgan Indian Investment Trust Plc
    1.08
    Sbi Life Insurance Co. Ltd
    2.11

    Metropolis Healthcare Latest News

    02 JUL 2025 | Wednesday

    Metropolis Healthcare Ltd - 542650 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    01 JUL 2025 | Tuesday

    Metropolis Healthcare Ltd - 542650 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    30 JUN 2025 | Monday

    Metropolis Healthcare Ltd - 542650 - Closure of Trading Window

    View More

    Metropolis Healthcare Share Price FAQs

    Metropolis Healthcare share price is ₹1734 in NSE and ₹1735.1 in BSE as on 3/7/2025.

    Metropolis Healthcare share price in the past 1-year return was -14.14. The Metropolis Healthcare share hit a 1-year low of Rs. 1315 and a 1-year high of Rs. 2318.3.

    The market cap of Metropolis Healthcare is Rs. 9002.65 Cr. as of 3/7/2025.

    The PE ratios of Metropolis Healthcare is 72.03 as of 3/7/2025.

    The PB ratios of Metropolis Healthcare is 7.22 as of 3/7/2025

    The Mutual Fund Shareholding in Metropolis Healthcare was 26.42% at the end of 3/7/2025.

    You can easily buy Metropolis Healthcare shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Metropolis Healthcare share price is ₹2318.3 and ₹1315 as of 3/7/2025.

    Please be aware that Metropolis Healthcare stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.27
    +0.48 (+0.74%)
    139.70
    -0.61 (-0.43%)
    690.40
    +1.85 (+0.27%)
    2,611.20
    -19.00 (-0.72%)
    167.52
    -0.71 (-0.42%)
    390.65
    -2.00 (-0.51%)
    165.91
    +0.03 (+0.02%)
    260.85
    +1.10 (+0.42%)
    426.25
    -0.70 (-0.16%)
    399.90
    -6.75 (-1.66%)
    Top Gainers
    7,565.00
    +124.00 (+1.67%)
    1,291.30
    +20.50 (+1.61%)
    4,310.60
    +66.90 (+1.58%)
    244.05
    +2.98 (+1.24%)
    12,752.00
    +130.00 (+1.03%)
    Top Losers
    1,810.20
    -46.60 (-2.51%)
    2,126.60
    -42.50 (-1.96%)
    910.15
    -12.85 (-1.39%)
    1,980.70
    -27.20 (-1.35%)
    1,046.10
    -13.80 (-1.30%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -